BioCentury | Sep 1, 2014
Company News

OrbusNeich management update

OrbusNeich , Hong Kong, China Business: Cardiovascular, Supply/Service Transitioned: B. Wayne Johnson to CEO from CEO while remaining president WIR Staff Cardiovascular...
BioCentury | Jun 23, 2014
Clinical News

Combo Dual Therapy Stent: Phase IV started

OrbusNeich said investigators began the open-label, international Phase IV REDUCE trial to compare the 3-month Combo Dual Therapy Stent vs. the standard 12-month Combo Dual Therapy Stent in about 1,500 patients with ACS. The Combo...
BioCentury | Apr 7, 2014
Clinical News

Combo Dual Therapy Stent: Completed postmarketing study enrollment

...polymer matrix from SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.), has CE Mark approval in Europe. OrbusNeich...
BioCentury | Mar 3, 2014
Clinical News

Combo Dual Therapy Stent: Pivotal trial started

...matrix from SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.), has CE Mark approval in the EU. OrbusNeich...
BioCentury | Apr 29, 2013
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

...pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's...
...CE Mark approval in Europe. Boston Scientific Corp. (NYSE:BSX, Natick, Mass.) markets the Taxus stent. OrbusNeich...
BioCentury | Mar 28, 2011
Company News

OrbusNeich, Masaryk Hospital cardiovascular news

...the hospital and Dr. Pavel Cervinka, head of the hospital's cardiology department, alleging defamation. Specifically, OrbusNeich...
...R stent after admitting it was flawed, leading to damage to OrbusNeich's business and reputation. OrbusNeich...
...and minimize restenosis, and has been commercially available in more than 60 countries since 2005. OrbusNeich...
BioCentury | Oct 25, 2010
Clinical News

Genous Bio-engineered R stent update

...NYSE:MDT, Minneapolis, Minn.). Genous has been commercially available in more than 60 countries since 2005. OrbusNeich...
BioCentury | Oct 11, 2010
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Completed Phase II enrollment

...OrbusNeich's stent utilizes the SynBiosys biodegradable polymer matrix from SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.). OrbusNeich...
BioCentury | Oct 11, 2010
Clinical News

Genous Bio-engineered R stent: Phase II/III data

...meeting in Washington. Genous has been commercially available in more than 60 countries since 2005. OrbusNeich...
BioCentury | Apr 26, 2010
Clinical News

Genous Bio-engineered Cobalt Chromium Stent regulatory update

...endothelial progenitors cells and form a functional epithelial layer to minimize restenosis and prevent thrombosis. OrbusNeich...
Items per page:
1 - 10 of 20
BioCentury | Sep 1, 2014
Company News

OrbusNeich management update

OrbusNeich , Hong Kong, China Business: Cardiovascular, Supply/Service Transitioned: B. Wayne Johnson to CEO from CEO while remaining president WIR Staff Cardiovascular...
BioCentury | Jun 23, 2014
Clinical News

Combo Dual Therapy Stent: Phase IV started

OrbusNeich said investigators began the open-label, international Phase IV REDUCE trial to compare the 3-month Combo Dual Therapy Stent vs. the standard 12-month Combo Dual Therapy Stent in about 1,500 patients with ACS. The Combo...
BioCentury | Apr 7, 2014
Clinical News

Combo Dual Therapy Stent: Completed postmarketing study enrollment

...polymer matrix from SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.), has CE Mark approval in Europe. OrbusNeich...
BioCentury | Mar 3, 2014
Clinical News

Combo Dual Therapy Stent: Pivotal trial started

...matrix from SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.), has CE Mark approval in the EU. OrbusNeich...
BioCentury | Apr 29, 2013
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

...pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's...
...CE Mark approval in Europe. Boston Scientific Corp. (NYSE:BSX, Natick, Mass.) markets the Taxus stent. OrbusNeich...
BioCentury | Mar 28, 2011
Company News

OrbusNeich, Masaryk Hospital cardiovascular news

...the hospital and Dr. Pavel Cervinka, head of the hospital's cardiology department, alleging defamation. Specifically, OrbusNeich...
...R stent after admitting it was flawed, leading to damage to OrbusNeich's business and reputation. OrbusNeich...
...and minimize restenosis, and has been commercially available in more than 60 countries since 2005. OrbusNeich...
BioCentury | Oct 25, 2010
Clinical News

Genous Bio-engineered R stent update

...NYSE:MDT, Minneapolis, Minn.). Genous has been commercially available in more than 60 countries since 2005. OrbusNeich...
BioCentury | Oct 11, 2010
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Completed Phase II enrollment

...OrbusNeich's stent utilizes the SynBiosys biodegradable polymer matrix from SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.). OrbusNeich...
BioCentury | Oct 11, 2010
Clinical News

Genous Bio-engineered R stent: Phase II/III data

...meeting in Washington. Genous has been commercially available in more than 60 countries since 2005. OrbusNeich...
BioCentury | Apr 26, 2010
Clinical News

Genous Bio-engineered Cobalt Chromium Stent regulatory update

...endothelial progenitors cells and form a functional epithelial layer to minimize restenosis and prevent thrombosis. OrbusNeich...
Items per page:
1 - 10 of 20